Asceneuron aims to address high unmet medical needs in neurodegenerative diseases such as orphan tauopathies, Alzheimer’s and Parkinson’s disease. Our pipeline is composed of innovative small-molecule therapeutics aiming to prevent disease progression in proteinopathies and reverse cognitive impairment in dementia.
PROTEINOPATHIES (Tau / α-Synuclein)
COGNITIVE DYSFUNCTION IN DEMENTIA
AD: Alzheimer's disease
LBD: Lewy Body Dementia
FTD: Frontotemporal dementia
PDD: Parkinson's disease dementia
PSP: Progressive Supranuclear Palsy